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There  are  more  vaccines  in development,  against  a greater  number  of  pathogens,  than  ever before.  A
challenge  with  this  exceptional  level  of activity  and  investment  is  how  to select  and  resource  the  most
promising  approaches  to  have  the  most  signiﬁcant  impact  on public  health.  The  WHO  Product  Develop-accine
andidate
roduct development
PC
MIC
ment  for Vaccines  Advisory  Committee  (PDVAC)  was  established  in 2014  to provide  strategic  advice  and
recommendations  to WHO  for  vaccines  in  clinical  development  that could  have  a signiﬁcant  impact  on
public  health  in low  and  middle  income  countries.  On 7–9th  September  2015,  PDVAC  was convened  for
the  second  time,  when  the committee  reviewed  vaccine  developments  in  24 disease  areas.  This report
summarises  the  key  recommendations  from  that  consultation.
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human pathogens [1]. PDVAC’s remit is to consider how to acceler-
ate vaccine candidates at the Phase 2 stage of clinical evaluation or
earlier, for disease areas where there is substantial disease burden
in low and middle income countries (LMICs), but where no vaccines
currently exist, and where there is some ongoing product devel-
opment activity which may  beneﬁt from guidance from WHO  [2].
One of the potential key outputs from PDVAC review is the recom-
mendation to generate a WHO  guidance document describing the
preferred product characteristics (PPCs) for a vaccine against a par-
ticular pathogen. These PPC documents describe WHO  preferences
for vaccines to be used in LMICs; in particular its indications, target
groups and features of desirable clinical data related to safety and
efﬁcacy. They are intended to provide early guidance to developers
at least 5–10 years from vaccine approval, and to ensure that, once
licensed, data are available to enable decision-making on use of the
vaccine in the populations that need it most.
2. The scope and objectives of the 2015 PDVAC meeting
The WHO  convened its second PDVAC meeting in Geneva, in
September 2015, involving subject matter experts from vaccine
industry, academia and public private partnerships. In the 12
months since its ﬁrst meeting, the vaccine research and develop-
ment landscape had shifted signiﬁcantly, with a renewed focus
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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n preparedness for emerging infectious diseases in the wake of
he 2014–2015 Ebola emergency. For this reason, the 2015 agenda
ncluded an overview of the unprecedented process and timeline
o interim efﬁcacy data for Ebola vaccines, reports from the ongo-
ng Phase III study, as well as a Target Product Proﬁle that is now
nalised and publically available [3]. In addition, the committee
as informed of efforts to establish a WHO  Blueprint for Emer-
ency R&D Preparedness and Research Response. Middle Eastern
espiratory Syndrome-coronavirus (MERS-CoV) was  reviewed as
n ongoing case study of an emerging pathogen, under the auspices
f this recently formed initiative.
Prior to the meeting, the committee reviewed 24 pathogen-
peciﬁc landscape analyses that outline the unmet public health
eed, current vaccine development status and product develop-
ent challenges. All of these documents are included in this special
accine supplement on pipeline vaccines, and are on the WHO
DVAC website. For 13 of these 24 pathogens, subject matter
xperts described the status of vaccine development in presenta-
ions to the committee. PDVAC’s remit is to consider which vaccines
re likely to have clinical proof of concept data within the next 3
ears and to identify areas where WHO  has a clear role to play in
ncreasing the likelihood that these vaccines will be used to reduce
he disease burden in LMICs. PDVAC is not a vaccine prioritisation
ommittee, but rather a committee to assess the vaccine pipeline
nd determine what activities or guidance may  best accelerate vac-
ines for diseases that are most prevalent in LMICs.
This report summarises the conclusions and recommendations
rom the meeting. It is not intended to be an in depth summary of
he product development status for each pathogen (for this, please
efer to the individual landscape analyses and meeting presenta-
ions on the WHO  website [2]). Also, many pathogens not discussed
y PDVAC remain an important priority for vaccine research and
evelopment.
. New vaccines for maternal immunisation on the horizon
Both Respiratory Syncytial Virus (RSV) and Group B Strepto-
occus (GBS) are pathogens for which there is major unmet public
ealth need, particularly for neonates and infants in LMICs. For
oth pathogens, maternal immunisation could reduce the risk
f neonatal infection and death by passive placental transfer of
aternal antibodies. Although new vaccines against these con-
itions may  establish a precedent for maternal immunisation as
he initial indication, other existing vaccines such as those against
nﬂuenza and tetanus have been recommended by the WHO  for
mmunisation of pregnant women. Indeed, in the case of inﬂuenza,
HO highlighted pregnant women as the highest priority target
roup for vaccination.
.1. RSV
RSV was highlighted at the inaugural PDVAC meeting as a
athogen for which there is signiﬁcant clinical pipeline activity,
nd likelihood of a candidate emerging for licensure in the near
erm. Novavax’s RSV F-protein based nanoparticle vaccine remains
he most advanced candidate, with a Phase III study in pregnant
omen that started at the end of 2015, following the demonstration
n a Phase II study [5] that palivizumab-competing antibody and
SV neutralising antibody were elicited and transferred to infants.
n addition, recent preliminary data in the elderly demonstrated
fﬁcacy, and a phase III trial has been initiated in that target pop-
lation (NCT02608502). GSK and J&J also have RSV F vaccines in
linical development that target pregnant women, and MedIm-
une is developing an RSV F vaccine for use in the elderly. A
umber of groups have RSV F vaccines in preclinical development,
ncluding NIAID. An RSV subunit vaccine containing the SH protein34 (2016) 2865–2869
(Immunovax) is also currently being evaluated in adults. A number
of live vaccines are in clinical development for active immunisa-
tion of infants and young children, including native RSV candidates
from which nonessential genes have been deleted, and an adeno-
virus vector containing the RSV F gene. Passive prophylaxis with
a long-half life monoclonal antibody developed by Medimmune is
currently being evaluated in a dose-escalation/pharmacokinetics
trial in healthy preterm infants (NCT02290340).
Following the 2014 PDVAC meeting, WHO  convened a consul-
tation to provide guidance on clinical endpoints and development
pathways for maternal and paediatric RSV vaccine candidates, with
a focus on considerations in LMICs [4]. In addition, WHO, PATH and
National Institute for Biological Standards and Control (NIBSC) are
collaborating to develop reference reagents, with a view to estab-
lishing International Standards. Efforts to develop PPCs, as well as
to propose a roadmap for RSV vaccines, are underway and will be
discussed during a WHO  consultation in 2016. Given the signiﬁcant
progress in RSV vaccine development, a speciﬁc RSV update will be
provided “For information” to WHO’s Strategic Advisory Group of
Experts (SAGE) in April 2016.
3.2. GBS
GBS is a signiﬁcant cause of infant mortality particularly in
the neonatal period, with most deaths occurring in LMICs, where
treatment with intrapartum antibiotic prophylaxis (IAP) is not
generally used. High levels of maternal anti-capsular polysaccha-
ride (CPS) IgG correlate with reduced neonatal disease risk, and
a vaccine against 5 of the 10 circulating serotypes may  protect
against up to 90% of disease. Two large pharmaceutical compa-
nies are currently engaged in GBS vaccine development, with Glaxo
SmithKline considering Phase III study designs for their candidate.
The proposed approach is to identify speciﬁc anti-CPS IgG thresh-
olds as clinical correlates of protection, based on estimation of
disease risk reduction, rather than conventional clinical disease
end-points. With this in mind, PDVAC recommended that WHO
develop guidance on the testing and development pathway for GBS
vaccines, including consensus on strategic goals, clinical trial design
considerations and development of PPCs. Key development con-
siderations include ethical issues in conducting a vaccine efﬁcacy
study in a population with high GBS incidence, such as parts of
Africa, where IAP is not the standard of care.
4. Advances in enteric vaccines
4.1. Shigella and enterotoxigenic Escherichia coli (ETEC)
Globally, there are nearly 1.7 billion cases of diarrhoeal disease
every year, many with acute and chronic effects. The Global Enteric
Multicenter Study (GEMS) was a large multi-country case-control
study of the aetiology of cases of moderate-to-severe diarrhoea
[6]). Molecular reanalysis of randomly selected samples collected
in the study, using qPCR rather than culture, conﬁrmed that ETEC
and Shigella are two of the most signiﬁcant pathogens that cause
moderate-to-severe diarrhoea among children <5 years old in
Africa and South Asia, accounting for around 40% of diarrhoea
episodes in 12–23 month olds. In addition to diarrhoeal disease,
ETEC and Shigella infections result in an estimated 4.6 million
children with moderate or severe stunting due to malnutrition,
accounting for an additional 31,000 deaths annually.
Killed (ETVAX [8]) or live attenuated (ACE527 [9]) whole vac-
cine approaches, in combination with the adjuvant Double Mutant
Heat Labile Toxin (dmLT), are the most advanced ETEC vaccine
candidates. Several Shigella vaccine candidates, based on live atten-
uated or sub-unit approaches, are also in clinical studies. Trials of
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hese vaccines are facing similar challenges to those for ETEC with
espect to requiring multi-valent approaches, assay standardisa-
ion and identifying correlates of protection, as well as in deﬁning
ppropriate clinical trial end-points and clinical trial design for
eld trials in endemic areas. In addition, it is uncertain whether
 stand-alone ETEC or Shigella vaccine would be implemented, or
hether developers should prioritise development of a combina-
ion ETEC/Shigella vaccine. The WHO  intends to expand its current
apacity to support consensus building, guidance and decision-
aking in this area, in readiness for the Phase III studies.
.2. Norovirus
The recently published MAL-ED study, that documented
he occurrence of community-associated non-severe diarrhoeal
pisodes in 7 sites in different countries, identiﬁed Norovirus,
peciﬁcally the G.II strain, as having the highest attributable frac-
ion [7]. Norovirus causes an estimated 200,000 deaths per year,
lobally. Takeda has the leading vaccine candidate, for which clini-
al proof of concept was demonstrated in a human challenge model.
his vaccine is entering Phase IIb clinical studies in adults and
aediatrics imminently. This bivalent candidate vaccine is based
n a combination of GI.1 and GII.4 VLPs and is designed to offer
ross-protection against the 25 human genotypes. However, ongo-
ng and expanded surveillance is needed to monitor circulating
train replacement and to ensure that the candidate is able to
rotect against any emerging genotypes, as well as to better doc-
ment the disease burden. With this in mind, PDVAC advised that
HO explore the possibility of incorporating Norovirus surveil-
ance within the WHO  rotavirus surveillance network.
. The Global Vaccine Action Plan (GVAP): vaccine
evelopment efforts in HIV, malaria, TB and Universal
nﬂuenza
The GVAP is a framework approved by the World Health Assem-
ly in 2012 to achieve the Decade of Vaccines vision in which all
ndividuals and communities live free from vaccine preventable
iseases [10]. Within this framework is a speciﬁc objective on
esearch and development, with indicators related to progress
owards vaccines against HIV, malaria, tuberculosis and a univer-
al vaccine against inﬂuenza. According to the GVAP monitoring
 evaluation framework, progress towards R&D related objectives
s conducted every second year. PDVAC scrutinises the progress
owards the R&D indicators and issues recommendations for the
VAP assessment report. As such, development efforts for these
accines are ‘standing items’ for PDVAC review.
.1. Human Immunodeﬁciency Virus (HIV)
Four HIV vaccine concepts have been tested in six efﬁcacy tri-
ls in the last 30 years. One of these, the RV144 study, evaluated
 heterologous prime boost regimen and demonstrated a modest
evel of efﬁcacy (31%). The P5 partnership was established in the
ake of the RV144 trial to further optimise the ALVAC/protein het-
rologous prime/boost approach with a different adjuvant. A Phase
/II study with this new regimen is underway in South Africa, with
greed go/no-go decision criteria to proceed to a phase III, based
n interim data expected in early 2016. The ﬁnal efﬁcacy read out
s expected in early 2020, following 2 years of follow up. PDVAC
ommended the major progress towards Phase 3 trials in HIV vac-
ines. It was acknowledged that novel approaches in the HIV ﬁeld
ad advanced vaccine development against other pathogens.34 (2016) 2865–2869 2867
5.2. Tuberculosis (TB)
The WHO  post-2015 global TB strategic goals aim for a 95%
reduction in TB mortality by 2035 worldwide and a 90% reduction in
TB incidence (compared with 2015 levels). It is acknowledged that
these reduction targets are not achievable without the develop-
ment of novel tools for TB control. With the failure of the MVA-85A
TB vaccine to show efﬁcacy, the TB vaccine community has re-
focused on early stage, translational research and experimental
medicine studies to evaluate a more diverse candidate portfolio
with respect to both antigens and delivery platforms. To accel-
erate evaluation and to reduce costs, novel clinical study designs
are being used to collect clinical proof of concept data in tar-
geted, high incidence populations. Recent modelling data indicates
that targeting vaccines to adolescents and adults may  have the
highest and earliest public health impact and cost-effectiveness,
and consensus is emerging that development of vaccines to pre-
vent pulmonary tuberculosis in this age population should be a
signiﬁcant focus. PDVAC noted the complexities from the policy
perspective with “improved BCG vaccines”, including issues related
to non-speciﬁc beneﬁcial effects ascribed to BCG vaccination. The
committee encouraged work on development pathways for the
adolescents/adult indication, noting that basic and translational
research should remain an important focus.
5.3. Malaria
The progress of the most advanced candidate, RTS,S/AS01, was
reviewed, noting that the European Medicines Agency issued a pos-
itive scientiﬁc opinion on the vaccine in July 2015. While the next
steps with RTS,S/AS01 are explored there remains interest in sec-
ond generation malaria vaccines. WHO  has published a malaria
vaccine PPC document outlining WHO’s preferences for second
generation malaria vaccines in two classes; ﬁrstly highly effective
vaccines to reduce morbidity and mortality, and secondly vaccines
to prevent transmission for the purpose of enabling malaria elim-
ination [11]. Progress with transmission blocking vaccine trials in
Mali and whole parasite vaccine development was highlighted.
While not included as one of the two  highest priorities, a few
groups are now exploring progression of vaccines designed to pre-
vent pregnancy-associated malaria. The pathways to licensure and
use of such vaccines are not yet well characterised. It was  noted that
Plasmodium vivax remains neglected for vaccine research activities,
despite the very substantial disease burden due to this malaria par-
asite, especially in Asia. It was  noted that the “Controlled Human
Malaria Infection” model remains an important approach for initial
screening of potential malaria vaccine candidates.
5.4. Universal inﬂuenza
PDVAC considered the case for an improved seasonal inﬂuenza
vaccine approach, which optimises the currently available vaccines
to improve the magnitude, quality and duration of the protec-
tive response and potentially offers protection for more than one
inﬂuenza season. However, licensure of seasonal vaccines is based,
in many jurisdictions, on achieving an established hemagglutina-
tion inhibition (HAI) threshold. Development of improved seasonal
vaccines may  represent lower hanging fruit in terms of regula-
tory acceptability, compared to the timelines for a truly universal
inﬂuenza vaccine. The committee advised WHO  to develop strate-
gic public health goals and PPCs for improved seasonal inﬂuenza
vaccines, and to provide guidance on data that would be needed to
establish improved performance of such vaccines. In addition, the
WHO  is convening its eighth meeting on development of inﬂuenza
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accines that induce broadly protective and long-lasting immune
esponses in August, 2016.
. The ﬁrst generation vaccine against dengue
There are four dengue serotypes, and all are capable of caus-
ng the full spectrum of disease. Life-long homotypic protection is
onferred after initial infection but heterotypic protection against
ther serotypes is short-lived. A second infection with a different
erotype is more likely to cause severe dengue disease, presum-
bly through antibody-dependent enhancement (ADE). There two
accine candidates soon to begin Phase 3 trials, and one candi-
ate, Sanoﬁ Pasteur’s CYD-TDV, which requires 3 immunizations
ver six month intervals, has recently been approved for use in
hose 9–45 years of age living in endemic areas. Overall this vaccine
ffered around 60% protection against dengue disease, with vari-
ble efﬁcacy by serostatus and age of vaccinee, infecting serotype,
nd severity of disease [12]. It will be reviewed by SAGE in 2016.
PDVAC considered the issue of trials of second generation vac-
ines, and whether or not there would be a need for comparability
tudies with the existing vaccine. It was noted that there are cir-
umstances in which randomised, placebo controlled studies may
e justiﬁed even when an efﬁcacious vaccine exists, depending on
 number of factors [13]. Related to this, WHO  is planning to ini-
iate a process in 2016 on trial design considerations for second
eneration dengue vaccines and their path to licensure.
. Pipeline vaccines that may  be biologically feasible, but
or which a robust investment case needs to be developed
o catalyse R&D
.1. Group A Streptococcus (GAS)
GAS causes a substantial disease burden, with approximately
8 million people suffering from a serious GAS disease, 1.8 million
ew cases each year and 517,000 deaths annually [14]. The great-
st mortality burden is due to rheumatic heart disease, but invasive
AS diseases such as maternal sepsis also contribute signiﬁcantly.
revious human challenge studies, as well as vaccine trials, suggest
hat it is biologically feasible to develop a vaccine, however vac-
ine development has been impeded by safety concerns regarding
he potential for induction of GAS-mediated autoimmune diseases
uch as acute rheumatic fever (ARF) and acute post-streptococcal
lomerulonephritis (APGN). Although a number of recombinant,
ultivalent vaccine candidates have been developed, they are
truggling to secure investment beyond early stage clinical studies.
PDVAC recommended that two separate investment cases be
eveloped by the GAS community to target investment from (i) the
ublic sector, based on prevention of severe outcomes in resource
oor settings such as southern Africa, parts of Asia and certain high
isk communities, including those in Australasia, and (ii) the private
ector, incorporating both the high income country (HIC) market
or prevention of pharyngitis due to GAS, and the LMIC market for
revention of cardiac disease. The outcomes of these 2 investment
ases will assist the GAS scientiﬁc community, PDVAC and funding
gencies in determining the optimal product development strategy
or GAS vaccines.
.2. Herpes simplex virus (HSV)
Herpes simplex virus type 2 (HSV-2) is an extremely common
exually transmitted infection (STI), affecting over 400 million peo-
le aged 15–49 years globally, with lifelong recurrence of genital
esions. HSV type 1 (HSV-1), which infects the majority of the
orld’s population, typically causes oral lesions but is also an34 (2016) 2865–2869
increasingly important cause of genital infection. Control of HSV-
2 infection is of particular concern for LMICs because it increases
both acquisition and transmission of HIV infection. Previous devel-
opment efforts for a prophylactic HSV vaccine did not show efﬁcacy
against HSV-2 but did demonstrate some efﬁcacy against HSV-1
[15], suggesting that a vaccine against this class of viruses is biolog-
ically feasible. Currently, therapeutic vaccine candidates are more
advanced than those with prophylactic indications, with one can-
didate demonstrating a 55% reduction in viral shedding.
PDVAC noted that development of a robust investment case,
including updated morbidity and mortality data on the global
burden of HSV-1, neonatal herpes, HSV-2 and HSV-associated
HIV infection, may  help to catalyse further vaccine development.
Updated global estimates of prevalent and incident HSV-2 infec-
tion were recently published [16], as have the ﬁrst WHO  global and
regional estimates of HSV-1 (including HSV-1 prevalence and inci-
dence, in those aged 0–49 years, and genital HSV-1, in ages 15–49
years [17]. Neonatal herpes estimates are underway. PDVAC also
recommended efforts to generate better primary data on neonatal
herpes in LMICs, in particular through including HSV infection in
the minimally invasive autopsy assessments to be undertaken by
the Child Health and Mortality Prevention Surveillance Network
(CHAMPS).
PDVAC noted that a major incentive for the development of
HSV vaccines, in addition to the public health burden directly
attributable to these viruses, is their potential to reduce HIV infec-
tion rates. In order to better understand the potential impact that
a prophylactic or therapeutic vaccine may  have on HIV transmis-
sion and disease, the WHO  is commissioning an updated systematic
review of the effects of HSV-2 infection on subsequent HIV inci-
dence. In addition, the WHO  and others in the HSV community
have collaborated to develop an STI vaccine roadmap (most recent
update included in this issue) and the elements required to formu-
late an HSV vaccine investment case, in order to incentivize funding
and pharmaceutical company engagement in development of these
vaccines.
8. Emerging infectious diseases, and the WHO  Vaccine
Preparedness Blueprint
The objective of the WHO  Vaccine Preparedness Blueprint is
to formulate a strategic roadmap and implementation plan that
enables circumvention of obstacles that typically impede pre-
emptive vaccine development prior to the onset of a public health
emergency, and to facilitate a timely and effective R&D response
when the inevitable future emergencies occur.
Some of the emerging pathogen areas presented to PDVAC, such
as MERS, Nipah and chikungunya viruses will be further assessed as
part of the WHO  Blueprint discussions. PDVAC will review vaccine-
related elements for these pathogens prior to Blueprint review,
whilst ensuring complementarity with guidance in development
related to drugs, diagnostics and non product-development related
research as part of the holistic R&D focus on emerging pathogens.
The ﬁrst of these, the WHO  Ebola Vaccine Target Product Proﬁles,
was ﬁnalised in December 2015. A draft PPC, and a consultation
meeting to initiate work on a roadmap towards a MERS vaccine
and emergency response occurred in December 2015.
9. Looking ahead – PDVAC in 2016
The pathogens to be reviewed in 2016 will focus on those for
which vaccines are most likely to enter clinical proof-of-concept
studies within the next three years, such as Clostridium difﬁcile.  The
recently published Phase III trials for the Helicobacter pylori [18]
and Enterovirus 71 [19] (EV71) candidates, both of which were
performed in China will also be discussed.
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In addition to the evaluation of new vaccines, PDVAC has a role
here ﬁrst generation vaccines are licensed but development of
mproved second generation products are needed for an ongoing
nmet public health need in LMICs. In keeping with this remit, the
roduct development efforts ongoing for second generation pneu-
ococcal vaccines, as well as for rotavirus will likely be discussed.
n the cases of dengue and malaria vaccines, PDVAC noted that
accine development for both diseases are entering a critical stage
hereby guidance on trial design and endpoints related to second
eneration vaccines will be needed, and recommended that WHO
nitiates development of such guidance.
In general, PDVAC noted that many important platform tech-
ologies, such as novel viral vectors, innovative antigen design
nd broadly neutralising antibody approaches, often emerge from
IV and malaria vaccine R&D. It is therefore imperative that
nformation on these potentially cross-cutting clinical portfo-
ios is communicated between ﬁelds. WHO  has begun to collate
ummary information on the global vaccines portfolios across
everal pathogen ﬁelds, including HIV, TB, malaria, respiratory
nd enteric pathogens available at: http://who.int/immunization/
esearch/vaccine pipeline tracker spreadsheet/en/.
The PDVAC review process offers a mechanism to ‘deep dive’ into
he product development issues and opportunities across a range of
athogens, and solicits guidance from experts in the vaccine ﬁeld.
here have been several exciting developments in the last year,
nd the vaccine community looks forward to progress in all of the
isease areas discussed. The next meeting of PDVAC is planned for
une 8–10, 2016.
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